Brainsway Ltd - ADR
BWAY
Get informed when a big investor buys or sells
+ FollowMarket Cap$674.45M
Close$
$3.71
74% downside
Current Fair Value
74% downsideOvervalued by 74% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $674.45 Million |
|---|---|
| Enterprise Value | $634.21 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.4 |
| Beta | 0.22 |
| Outstanding Shares | 19,083,333 |
Return
| Return on Equity | 12.46% |
|---|---|
| Return on Assets | 8.07% |
| Return on Invested Capital | 5.95% |
Valuation & Multiples
| P/E Ratio | 71.78 |
|---|---|
| PEG | 67.17 |
| Price to Sales | 4.76 |
| Price to Book Ratio | 4.76 |
| Enterprise Value to Revenue | 10.48 |
| Enterprise Value to EBIT | 114.1 |
| Enterprise Value to Net Income | 67 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.24 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 13, 2026
EPS Estimate
$0.05
Average shareholder expectationRevenue Estimate
$14.63 M
Average shareholder expectationNext Earnings Call
Expected Date
August 12, 2026
EPS Estimate
$0.08
Average shareholder expectationRevenue Estimate
$16.30 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 63.88%▲ 32.73% |
|---|---|
| Total Invested | $155.59M▲ 38.20% |
| Investors Holding | 55▲ 11.00% |
ESG Score
No data
About Brainsway Ltd.
CEO: Christopher von Jako Brainsway Ltd. is a commercial stage medical device company, which focuses on the development and sale of non-invasive neuromodulation products using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the tr...